What is HC Wainwright’s Forecast for HRTX Q4 Earnings?

Posted by George Bondi on Jun 4th, 2026

Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) – Equities researchers at HC Wainwright issued their Q4 2026 earnings estimates for Heron Therapeutics in a research report issued to clients and investors on Wednesday, June 3rd. HC Wainwright analyst B. Folkes forecasts that the biotechnology company will post earnings of ($0.01) per share for the quarter. HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.05) per share.

Other analysts also recently issued research reports about the company. Zacks Research downgraded Heron Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, April 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Needham & Company LLC lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $2.50.

Read Our Latest Stock Analysis on Heron Therapeutics

Heron Therapeutics Price Performance

Shares of Heron Therapeutics stock opened at $0.45 on Thursday. The company has a current ratio of 2.53, a quick ratio of 1.51 and a debt-to-equity ratio of 17.51. The company’s 50-day moving average price is $0.92 and its two-hundred day moving average price is $1.11. Heron Therapeutics has a 52 week low of $0.43 and a 52 week high of $2.30. The stock has a market cap of $84.57 million, a PE ratio of -2.48 and a beta of 1.58.

Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Heron Therapeutics had a negative return on equity of 7,747.30% and a negative net margin of 20.53%.The business had revenue of $34.71 million during the quarter, compared to the consensus estimate of $36.72 million.

Institutional Trading of Heron Therapeutics

Hedge funds have recently bought and sold shares of the company. Baker BROS. Advisors LP purchased a new stake in Heron Therapeutics during the third quarter valued at about $5,357,000. Citigroup Inc. grew its stake in Heron Therapeutics by 4,666.9% during the 3rd quarter. Citigroup Inc. now owns 2,476,529 shares of the biotechnology company’s stock valued at $3,120,000 after acquiring an additional 2,424,576 shares in the last quarter. JW Asset Management LLC grew its stake in Heron Therapeutics by 40.8% during the 3rd quarter. JW Asset Management LLC now owns 3,292,633 shares of the biotechnology company’s stock valued at $4,149,000 after acquiring an additional 954,890 shares in the last quarter. New York State Common Retirement Fund grew its stake in Heron Therapeutics by 46.4% during the 3rd quarter. New York State Common Retirement Fund now owns 2,576,716 shares of the biotechnology company’s stock valued at $3,247,000 after acquiring an additional 816,671 shares in the last quarter. Finally, Clearline Capital LP grew its stake in Heron Therapeutics by 1,033.1% during the 3rd quarter. Clearline Capital LP now owns 9,712,527 shares of the biotechnology company’s stock valued at $12,238,000 after acquiring an additional 8,855,361 shares in the last quarter. 80.01% of the stock is owned by hedge funds and other institutional investors.

Heron Therapeutics Company Profile

(Get Free Report)

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.